» Articles » PMID: 16035619

Association of Alphavbeta3 Integrin Expression with the Metastatic Potential and Migratory and Chemotactic Ability of Human Osteosarcoma Cells

Overview
Specialty Oncology
Date 2005 Jul 23
PMID 16035619
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Expression of adhesion molecules such as alphavbeta3 integrin has been associated with the metastatic potential of tumor cells. The purpose of this study was to determine whether alphavbeta3 expression correlated with the metastatic potential of human osteosarcoma cells.

Materials And Methods: We developed a series of sublines (LM2-LM7) from human osteosarcoma SAOS parental cells, with progressively increasing potential to form lung metastases in nude mice after intravenous injection. SAOS parental and LM2 cells were poorly metastatic, but LM7 cells resulted in visible metastatic lung nodules by 6-8 weeks. We quantified alphavbeta3 integrin expression using flow cytometry.

Results: alphavbeta3 expression correlated with the metastatic potential of the cells, with LM7 cells showing the highest expression. LM7 cell adhesion to vitronectin decreased after treatment with echistatin, a RGD-containing peptide antagonist of alphavbeta3. LM7 cells demonstrated higher chemotactic activity than SAOS cells to a homogenate made from lung tissue. This chemotactic activity was also inhibited by echistatin. These data indicated that alphavbeta3 was critical for the migration of LM7 cells to the lung homogenate. Chemotaxis to a liver homogenate was the same for LM7 and SAOS cells. Migration of LM7 cells through lung endothelial cells was higher than that through liver endothelial cells, and echistatin again inhibited this migration.

Conclusions: alphavbeta3 integrin expression may play a role in the metastatic potential of osteosarcoma cells by enhancing the ability of the cells to migrate specifically to the lung. Alphavbeta3 integrin may therefore be a potential new target for osteosarcoma.

Citing Articles

Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.

Schott C, Koehne A, Sayles L, Young E, Luck C, Yu K Clin Cancer Res. 2023; 30(4):849-864.

PMID: 37703185 PMC: 10870121. DOI: 10.1158/1078-0432.CCR-23-0873.


A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.

Talbot L, Chabot A, Funk A, Nguyen P, Wagner J, Ross A Front Immunol. 2021; 12:691741.

PMID: 34211478 PMC: 8239305. DOI: 10.3389/fimmu.2021.691741.


Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.

Fan T, Roberts R, Lizardo M Front Oncol. 2020; 10:13.

PMID: 32082995 PMC: 7006476. DOI: 10.3389/fonc.2020.00013.


Long noncoding RNA CASC11 promotes osteosarcoma metastasis by suppressing degradation of snail mRNA.

Song K, Yuan X, Li G, Ma M, Sun J Am J Cancer Res. 2019; 9(2):300-311.

PMID: 30906630 PMC: 6405980.


Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma.

Shi K, Wang S, Shen B, Yu F, Weng D, Lin J World J Surg Oncol. 2019; 17(1):23.

PMID: 30691475 PMC: 6350278. DOI: 10.1186/s12957-019-1566-z.


References
1.
Link M, Goorin A, Miser A, Green A, Pratt C, Belasco J . The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314(25):1600-6. DOI: 10.1056/NEJM198606193142502. View

2.
Langley R, Ramirez K, Tsan R, Van Arsdall M, Nilsson M, Fidler I . Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res. 2003; 63(11):2971-6. View

3.
Curran S, Murray G . Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999; 189(3):300-8. DOI: 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C. View

4.
Kumar C, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T . Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 2001; 61(5):2232-8. View

5.
Deryugina E, Bourdon M, Jungwirth K, Smith J, Strongin A . Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer. 2000; 86(1):15-23. DOI: 10.1002/(sici)1097-0215(20000401)86:1<15::aid-ijc3>3.0.co;2-b. View